Avid Bioservices Inc (CDMO)

[Fire Fox]

Thank you FTM for finding these AACR Abstracts.

When the PRs from AACR come out on April 8-10 regarding these pre-clinical studies, the market will probably react with a yawn, but this kind of detailed understanding of how Bavi affects the immune system and why Betabodies will be the next therapeutic generation of drugs after Bavi, will further educate (and hopefully motivate) potential BP partners as to both the depth and the potential of the anti-PS platform.

If I understand correctly, the first abstract you posted is important because it establishes that Bavi does trigger the differentiation of MDSCs into DCs (Dendritic Cells), which in turn demonstrates that the Bavi MOA is working at the top of the immuno-therapeutic chain of events. Is this correct?

By contrast, competing immunotherapies have their effect much further down the chain. Correct?